To date, there are no reliable diagnostic blood markers of adult vasculitis. To date, the diagnosis of vasculitis is based on invasive procedure, biopsy of affected tissues potentially at risk of complication . In addition, there are no reliable biomarkers to predict the evolution of vasculitis (relapse, refractory form ...) necessary for the management of patients (type of treatment, duration ..) Prospective study, monocentric (CHU de Tours), non-interventional, aimed at finding diagnostic and prognostic biomarkers (both metabolomic and immunologic) in adult vasculitis patients.
Specimen will be collected at diagnosis, month 1, month 3, and month12 and at the time of a possible relapse. 14 ml of additional blood during a blood puncture made for routine care will be collected at each visit as well as clinical data.
Study Type
OBSERVATIONAL
Enrollment
225
4 blood sampling per patient and an additional one in case of relapse
University hospital
Tours, France
RECRUITINGcytokine/chemokine/metabolite concentrations
Analysis by méthod Luminex
Time frame: Baseline
cytokine/chemokine/metabolite concentrations
Analysis by méthod Luminex
Time frame: Month 1
cytokine/chemokine/metabolite concentrations
Analysis by méthod Luminex
Time frame: Month 3
cytokine/chemokine/metabolite concentrations
Analysis by méthod Luminex
Time frame: Month 12
cytokine/chemokine/metabolite concentrations
Analysis by méthod Luminex
Time frame: date of relapse assessed up to 12 months
percentage of different non-conventional T cell populations
study by flow cytometry
Time frame: Baseline
percentage of different non-conventional T cell populations
study by flow cytometry
Time frame: Month 1
percentage of different non-conventional T cell populations
study by flow cytometry
Time frame: Month 3
percentage of different non-conventional T cell populations
study by flow cytometry
Time frame: Month 12
percentage of different non-conventional T cell populations
study by flow cytometry
Time frame: date of relapse assessed up to 12 months
cytokine/chemokine/metabolite concentrations
identify a metabolomic blood profile for the prognosis of vasculitis
Time frame: baseline
cytokine/chemokine/metabolite concentrations
identify a metabolomic blood profile for the prognosis of vasculitis
Time frame: Month 1
cytokine/chemokine/metabolite concentrations
identify a metabolomic blood profile for the prognosis of vasculitis
Time frame: Month 3
cytokine/chemokine/metabolite concentrations
identify a metabolomic blood profile for the prognosis of vasculitis
Time frame: Month 12
cytokine/chemokine/metabolite concentrations
identify a metabolomic blood profile for the prognosis of vasculitis
Time frame: date of relapse assessed up to 12 months
percentage of different non-conventional T cell populations
identify an immunological blood profile for the prognosis of vasculitis
Time frame: baseline
percentage of different non-conventional T cell populations
identify an immunological blood profile for the prognosis of vasculitis
Time frame: Month 1
percentage of different non-conventional T cell populations
identify an immunological blood profile for the prognosis of vasculitis
Time frame: Month 3
percentage of different non-conventional T cell populations
identify an immunological blood profile for the prognosis of vasculitis
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Month 12
percentage of different non-conventional T cell populations
identify an immunological blood profile for the prognosis of vasculitis
Time frame: date of relapse assessed up to 12 months
metabolomic pathway
Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: baseline
metabolomic pathway
Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: Month 1
metabolomic pathway
Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: Month 3
metabolomic pathway
Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: Month 12
metabolomic pathway
Identify a metabolomic pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: date of relapse assessed up to 12 months
immunological pathway
Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: baseline
immunological pathway
Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: Month 1
immunological pathway
Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: Month 3
immunological pathway
Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: Month 12
immunological pathway
Identify an immunological pathway involved in the pathophysiology of vasculitis that could be a target for therapy.
Time frame: date of relapse assessed up to 12 months